^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Fovista (pegpleranib)

i
Other names: E-10030, OAP-030, E01AJ, X01E, E10030
Associations
Company:
Astellas, Roche
Drug class:
PDGFR inhibitor
Associations
9ms
Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology. (PubMed, Int J Nanomedicine)
Aptamers, including E10030, RBM-007, AS1411, and avacincaptad pegol, targeting other angiogenesis-related biomarkers have also been discovered and subjected to clinical trials. Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.
Review • Journal
|
TFRC • TGFB1 (Transforming Growth Factor Beta 1) • NCL (Nucleolin) • CTGF (Connective tissue growth factor)
|
QN-165 • Fovista (pegpleranib) • umedaptanib pegol (RBM-007)